Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

17.84 -0.32 (-1.76%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Price and Volume

Volume	1,192,630
Open	18.22
Bid (Size)	17.60 (200)
Ask (Size)	20.00 (300)
Prev. Close	18.16
Today's Range	17.65 - 18.48
52wk Range	10.57 - 26.18
Shares Outstanding	121,640,069
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

November 06, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Board and Executive Leadership Updates

November 06, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	-14.4%	-14.4%
1 Month	+16.1%	+16.1%
3 Month	+15.5%	+15.5%
6 Month	+28.1%	+28.1%
1 Year	-30.4%	-30.4%

More News

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate ↗

October 14, 2025

Via Benzinga

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

October 13, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

August 11, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

July 07, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

May 06, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

What Happened To Denali Therapeutics Stock Wednesday? ↗

April 02, 2025

Via Benzinga

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

April 02, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback ↗

March 06, 2025

Via Benzinga

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

February 27, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

February 06, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

January 30, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Why Is Denali Therapeutics Stock Trading Higher On Wednesday? ↗

January 15, 2025

Via Benzinga

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

January 13, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

January 08, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗

January 07, 2025

Via Benzinga

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗

January 07, 2025

Via Investor's Business Daily

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

January 06, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

Via Benzinga

This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday ↗

January 03, 2025

Via Benzinga

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

December 05, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

November 06, 2024

From Denali Therapeutics Inc.

Via GlobeNewswire

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why ↗

October 10, 2024

Via Benzinga

A Biotech Breakout Will Be Led By Small Caps ↗

September 23, 2024

Via Talk Markets

Frequently Asked Questions

Is Denali Therapeutics Inc. - Common Stock publicly traded?

Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Denali Therapeutics Inc. - Common Stock trade on?

Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?

The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market

What is the current price of Denali Therapeutics Inc. - Common Stock?

The current price of Denali Therapeutics Inc. - Common Stock is 17.84

When was Denali Therapeutics Inc. - Common Stock last traded?

The last trade of Denali Therapeutics Inc. - Common Stock was at 12/02/25 04:00 PM ET

What is the market capitalization of Denali Therapeutics Inc. - Common Stock?

The market capitalization of Denali Therapeutics Inc. - Common Stock is 2.17B

How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?

Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.